July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Untargeted large spot half-fluence photodynamic therapy for chronic central serous chorioretinopathy
Author Affiliations & Notes
  • Aseel Hamoud Hamoud Bedan
    eye ear and mouth unit, Maidstone and Tunbridge Wells NHS trust, Maidstone, Kent, United Kingdom
  • Goncalo Almeida
    eye ear and mouth unit, Maidstone and Tunbridge Wells NHS trust, Maidstone, Kent, United Kingdom
  • Footnotes
    Commercial Relationships   Aseel Hamoud Bedan, None; Goncalo Almeida, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3132. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aseel Hamoud Hamoud Bedan, Goncalo Almeida; Untargeted large spot half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3132.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report functional and anatomic results of the use of untargeted large spot half-fluence photodynamic therapy PDT with verteporfin for chronic central serous chorioretinopathy CSC.

Methods : A retrospective analysis of 14 eyes of 13 patients with chronic CSC was performed. All eyes received half-fluence PDT centered on the fovea with a large spot (3000). Best corrected visual acuity, central foveal thickness, and macular volume were evaluated.

Results : We included a total of 13 patients (n=14 eyes) in our study. The mean age at baseline was 44 years-old. 64% patients were males and 36% were females. The mean duration of the CSR was 8 months (range 2-48 months) before treatment. The BCVA after the treatment improved from 0.33 logMAR to 0.05 logMAR (P<0.000003). The CRT measured by OCT scan improved in 92% of patients by the end of the treatment. The mean CMT changed from 368 µm pre- treatment to 158 µm post- treatment (P< 0.00126). Macular volume changed from 8.4 to 7.4 (P< 0.000223).
At the end of the follow-up all eyes (100%) showed resolution of the subretinal fluid. There was no visual loss secondary to PDT, nor any other adverse events.

Conclusions : The results aim to demonstrate a new approach for treating chronic CSR, by using a large spot centred on the fovea. The results suggest validity of the treatment in the short-term, but long-term data needs to be collected. We believe that the advantage of administering PDT centred on the fovea with a large spot is that it more appropriately addresses the primary pathophysiologic process by reducing globally the hyper perfusion to the fovea. Limitations of the new technique might include late vision loss, however the authors believe that by administering it half-fluence such risk might be reduced.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×